2010
DOI: 10.1590/s0100-879x2010007500108
|View full text |Cite
|
Sign up to set email alerts
|

In vitro activity of hypnophilin from Lentinus strigosus: a potential prototype for Chagas disease and leishmaniasis chemotherapy

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
15
0

Year Published

2013
2013
2021
2021

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 18 publications
(15 citation statements)
references
References 20 publications
(24 reference statements)
0
15
0
Order By: Relevance
“…Terpenoids isolated from Lentinus strigosus and lanostane-type triterpenes isolated from Astraeus hygrometricus are some examples of compounds with promising activity against protozoan parasites such as T. cruzi and Leishmania [9, 24, 27]. …”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Terpenoids isolated from Lentinus strigosus and lanostane-type triterpenes isolated from Astraeus hygrometricus are some examples of compounds with promising activity against protozoan parasites such as T. cruzi and Leishmania [9, 24, 27]. …”
Section: Discussionmentioning
confidence: 99%
“…Considering that natural products have been providing interesting scaffolds for protozoan diseases, herein we investigated the potential of basidiomycetes, a rich source for antimicrobial compounds. For example, hypnofylline and panepoxidone isolated from the basidiomycete Lentinus strigosus and an ergosterol peroxide isolated from Pleurotus ostreatus have demonstrated anti- T. cruzi activities [9, 10]. Considering the genus Pleurotus , a number of secondary metabolites have been isolated with different biological properties, such as antitumor, antileishmanial, antimicrobial, anti-inflammatory and antitrypanosomal activities among others [1014].…”
Section: Introductionmentioning
confidence: 99%
“…To date, a very limited approach has been made to establish the mushrooms or mushroom-derived metabolites as therapeutic or immunostimulatory agents against Leishmania infection. As few as only seven reports, including three from our group, have been documented up to 2015 regarding the antileishmanial effect of extracts or active constituents of wild mushrooms (10)(11)(12)(13)(14)(15)(16). The first breakthrough was made by Jin and Zjawiony in 2006, when they isolated a novel compound, 5-heptadeca-8=Z,11=Z,16-trienylresorcinol, from a polypore mushroom, Merulius incarnatus Schweinitz 1822 (Corticiaceae), which inhibited the Leishmania growth in vitro (50% inhibitory concentration [IC 50 ] of 3.6 g/ml) with no toxicity on Vero cells up to 25 g/ml (10).…”
mentioning
confidence: 99%
“…There are just few studies describing the antiprotozoal activity of natural products against amastigote form of T. cruzi and most of those investigations have been conducted under in vitro conditions [2022]. In the performed bioassays, the in vivo antiprotozoal activity of chloroform extract of C. papaya seeds during the subacute and chronic phase of Chagas' disease was evaluated.…”
Section: Resultsmentioning
confidence: 99%
“…This fraction was reported as not cytotoxic, mutagenic, or genotoxic [20]. Another compound with antiprotozoal activity against the amastigote stage in vitro is the terpenoid hypnophilin, purified from Lentinus strigosus , which demonstrated a significant inhibitory activity over T. cruzi tripanotion reductase [22]. …”
Section: Resultsmentioning
confidence: 99%